Erez Israeli explains how Dr. Reddy's approached commercial readiness for its generic semaglutide launch in Canada and what vertical integration in peptide manufacturing means for the GLP-1 market.
Erez Israeli
Advertisement
Erez Israeli is chief executive officer of Dr. Reddy's Laboratories.
Articles by Erez Israeli
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Supply Chain Signal: Domestic Manufacturing and the German Pricing Standoff
2
How Lilly's AtaiBeckley Deal Accelerates Psychedelic Drug Commercialization Push
3
Cencora's Brent Wilhelm on the Inventory Paradox Behind Drug Shortages
4
Mid-Year Check-In: Will Pharma M&A Keep Pace?
5